1
|
Tsuda T, Ichikawa T, Matsumoto M, Mizusihima I, Azechi K, Takata N, Murayama N, Hayashi K, Hirai T, Seto Z, Tokui K, Masaki Y, Taka C, Okazawa S, Kambara K, Imanishi S, Taniguchi H, Miwa T, Hayashi R, Matsui S, Inomata M. An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma. Discov Oncol 2024; 15:382. [PMID: 39207576 PMCID: PMC11362448 DOI: 10.1007/s12672-024-01046-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 05/20/2024] [Indexed: 09/04/2024] Open
Abstract
BACKGROUND Pulmonary sarcomatoid carcinoma is a rare tumor that is resistant to cytotoxic agents. This observational study aimed to evaluate the detection rate of driver gene alteration and the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma. METHODS We established a database of patients with pulmonary sarcomatoid carcinoma and their clinical information, including EGFR mutation, ALK fusion gene, ROS1 fusion gene, BRAF mutation, and MET exon 14 skipping mutation. The present study retrieved and analyzed the data of patients with pulmonary sarcomatoid carcinoma in whom driver gene alterations were evaluated, and the survival duration after the initiation of treatment with targeted therapy was examined. RESULTS A total of 44 patients were included in the present study. The EGFR mutation, ALK fusion gene, and MET exon 14 skipping mutation were detected in 2/43 patients (4.7%), 2/34 patients (5.9%), and 2/16 patients (12.5%), respectively. The ROS1 fusion gene (0/18 patients) and BRAF mutation (0/15 patients) were not detected. Female patients (P = 0.063, Fisher's exact test) and patients without smoking history (P = 0.025, Fisher's exact test) were the dominant groups in which any driver mutation was detected. Five patients with driver gene alterations were treated with targeted therapy. Progression-free survival (PFS) was 1.3 months and 1.6 months in 2 of the patients treated with gefitinib. Two patients with the ALK fusion gene showed 2.1 and 14.0 months of PFS from the initiation of treatment with crizotinib, and a patient with the MET exon 14 skipping mutation showed 9.7 months of PFS from the initiation of treatment with tepotinib. CONCLUSION The EGFR mutation, ALK fusion gene, and MET exon 14 skipping mutation were detected in patients with pulmonary sarcomatoid carcinoma in clinical practice, and some patients achieved long survival times after receiving targeted therapy. Further investigation is necessary to evaluate the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma.
Collapse
Affiliation(s)
- Takeshi Tsuda
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan
| | - Tomomi Ichikawa
- Respiratory and Allergy Medicine, Toyama Red Cross Hospital, Toyama City, Japan
| | - Masahiro Matsumoto
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Isami Mizusihima
- Respiratory and Allergy Medicine, Toyama Red Cross Hospital, Toyama City, Japan
| | - Kenji Azechi
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan
| | - Naoki Takata
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan
| | - Nozomu Murayama
- Respiratory and Allergy Medicine, Toyama Red Cross Hospital, Toyama City, Japan
| | - Kana Hayashi
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Takahiro Hirai
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Zenta Seto
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Kotaro Tokui
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Yasuaki Masaki
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan
| | - Chihiro Taka
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Seisuke Okazawa
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Kenta Kambara
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Shingo Imanishi
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Hirokazu Taniguchi
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama City, Japan
| | - Toshiro Miwa
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Ryuji Hayashi
- Department of Medical Oncology, Toyama University Hospital, Toyama City, Japan
| | - Shoko Matsui
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan
| | - Minehiko Inomata
- First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan.
| |
Collapse
|
2
|
Wang F, Yu X, Han Y, Gong C, Yan D, Yang L, Li J, Liu S. Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study. BMC Pulm Med 2023; 23:262. [PMID: 37454075 DOI: 10.1186/s12890-023-02541-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 06/28/2023] [Indexed: 07/18/2023] Open
Abstract
OBJECTIVES Pulmonary sarcomatoid carcinoma (PSC) is a rare histological type of non-small cell lung cancer (NSCLC). There are no specific treatment guidelines for PSC. For advanced PSC (stage II-IV), the role of chemotherapy is still controversial. The purpose of this study was to investigate the effect of chemotherapy on the prognosis of advanced PSC. METHODS A total of 960 patients with advanced PSC from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2019 were enrolled in this study. To investigate the prognostic factors, the Cox proportional hazard regression model was conducted. A total of 642 cases were obtained after propensity score matching (PSM). The Kaplan‒Meier method was applied to compare overall survival (OS) and cancer-specific survival (CSS). RESULTS For all 960 cases included in this study, the Cox proportional hazard model was applied for prognostic analysis. Univariate and multivariate analyses showed that stage, T stage, N stage, M stage, surgery, and chemotherapy were prognostic factors for OS and CSS (P < 0.05). A total of 642 cases were obtained after PSM, with no significant difference between the two groups for all variables. Kaplan‒Meier curves indicated that for OS and CSS, the prognosis was significantly better in the chemotherapy group than in the no-chemotherapy group. CONCLUSIONS For advanced PSC, chemotherapy can significantly improve the OS and CSS of patients. Chemotherapy should be an important part of PSC treatment.
Collapse
Affiliation(s)
- Feng Wang
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China
| | - Xiangyang Yu
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Yi Han
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China
| | - Changfan Gong
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China
| | - Dongjie Yan
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China
| | - Lei Yang
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China
| | - Jie Li
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China.
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China.
| | - Shuku Liu
- Beijing Chest Hospital, Capital Medical University, Beijing, 101125, China.
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China.
| |
Collapse
|
3
|
Alejo AL, Patel RA, Pandya KK, Bodrya K, Goldstein L, Hemrock L. Asbestos Exposure and Development of Pulmonary Pleomorphic Carcinoma in a Non-smoker: A Rare Non-small Cell Lung Cancer. Cureus 2023; 15:e37860. [PMID: 37213984 PMCID: PMC10199346 DOI: 10.7759/cureus.37860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2023] [Indexed: 05/23/2023] Open
Abstract
Pulmonary pleomorphic carcinoma (PPC) is a subtype of non-small cell lung cancer that is extremely rare and carries a poor prognosis due to its inadequate response to treatment. Patients that present with PPC often exhibit similar symptoms of other malignancies of the lung, making it hard for clinicians to distinguish between each type. However, cytology and gene mutation testing are two approaches that can aid physicians in an accurate and definitive diagnosis. We present a case of an 88-year-old male patient with a diagnosis of pulmonary pleomorphic carcinoma after experiencing recurrent sanguineous pleural effusions. The patient had no smoking history but did have a history of asbestos exposure and pulmonary fibrosis. The patient underwent thoracotomy with pleurodesis and analysis of the surgical pleural biopsy specimen stained positive for markers indicative of PPC. The pathology report was also consistent with the associated cell morphology. Lung cancer is the leading cause of mortality due to cancer in the United States, and exposure to certain substances contributes to the development of these poorly treatable lung malignancies. Smoking and asbestos exposure are well known to act synergistically with each other as risk factors in developing these lung malignancies. In addition to clinical suspicion, screening for these risk factors with laboratory values and imaging is important to diagnose these rare cases of lung malignancies.
Collapse
Affiliation(s)
- Andrew L Alejo
- College of Medicine, Northeast Ohio Medical University, Rootstown, USA
| | - Riya A Patel
- Internal Medicine, Trumbull Regional Medical Center, Warren, USA
| | | | - Krishna Bodrya
- Internal Medicine, Trumbull Regional Medical Center, Warren, USA
| | | | - Lori Hemrock
- Internal Medicine, Trumbull Regional Medical Center, Warren, USA
| |
Collapse
|
4
|
Sonehara K, Nozawa S, Suzuki Y, Araki T, Komatsu M, Tateishi K, Hanaoka M. Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement. Case Rep Oncol 2023; 16:939-945. [PMID: 37900841 PMCID: PMC10601751 DOI: 10.1159/000532101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 07/10/2023] [Indexed: 10/31/2023] Open
Abstract
Pulmonary spindle cell carcinoma is a subtype of pulmonary sarcomatoid carcinoma and a very rare tumor type with a poor prognosis. A few case reports have documented patients with pulmonary sarcomatoid carcinoma with anaplastic lymphoma kinase rearrangement, and the efficacy and outcomes of anaplastic lymphoma kinase inhibitors remain unclear. Herein, we present the case of a 60-year-old woman with stage IVB disease who was diagnosed with a metastatic brain tumor. This patient showed high levels of programmed cell death ligand 1 expression and anaplastic lymphoma kinase rearrangement and received pembrolizumab as the first-line treatment. Three weeks later, pembrolizumab failed to reduce the size of the primary pulmonary tumor, and the patient's general condition did not improve. The patient received alectinib as the second-line treatment. Two months later, multiple brain metastases were observed. Hence, whole-brain irradiation was performed as treatment for multiple brain metastases, while another anaplastic lymphoma kinase inhibitor was administered; however, both treatments remained ineffective. The patient eventually died 9 months after the initiation of first-line treatment. The present case report describes the therapeutic course of a patient with pulmonary spindle cell carcinoma with an anaplastic lymphoma kinase rearrangement.
Collapse
Affiliation(s)
- Kei Sonehara
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Shuhei Nozawa
- Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan
| | - Yusuke Suzuki
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Taisuke Araki
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Masamichi Komatsu
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Kazunari Tateishi
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Masayuki Hanaoka
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
5
|
Li X, Wu D, Liu H, Chen J. Pulmonary sarcomatoid carcinoma: progress, treatment and expectations. Ther Adv Med Oncol 2020; 12:1758835920950207. [PMID: 32922522 PMCID: PMC7450456 DOI: 10.1177/1758835920950207] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 07/23/2020] [Indexed: 01/10/2023] Open
Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1-0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 (EGFR/VEGFR2), anaplastic lymphoma kinase (ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 (PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.
Collapse
Affiliation(s)
- Xin Li
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China
| | - Di Wu
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China
| | - Hongyu Liu
- Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Medical University General Hospital, Tianjin, China
| | - Jun Chen
- Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road no.154, Heping District, Tianjin 300052, China
| |
Collapse
|
6
|
Iijima Y, Nakajima Y, Kinoshita H, Nishimura Y, Iizuka T, Akiyama H, Hirata T. Clinicopathological Analysis of 17 Surgically Resected Pulmonary Pleomorphic Carcinoma Cases. Ann Thorac Cardiovasc Surg 2020; 27:1-9. [PMID: 32493871 PMCID: PMC8043029 DOI: 10.5761/atcs.oa.20-00018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
OBJECTIVES To determine the outcomes and prognostic factors associated with pulmonary resection of pulmonary pleomorphic carcinoma (PPC). METHODS During 2008-2017, 17 patients underwent pulmonary resection for primary PPC at the Saitama Cancer Center, Japan. We investigated clinicopathological characteristics and outcomes of these cases. Overall survival (OS) and disease-free survival (DFS) rates were determined using Kaplan-Meier method and compared using log-rank test. Univariate analysis was performed to identify prognostic factors. RESULTS The 5-year OS and DFS rates were 27.2% and 51.0%, respectively. The median follow-up period was 30.8±24.9 (3.6-92.8) months after pulmonary resections. Patients with disease-free interval (DFI) <1 year of resection had poorer prognosis than those without (p = 0.001). Patients with N2 status and adenocarcinoma components had significantly poorer disease-free prognosis than their counterparts (p = 0.021 and p = 0.019, respectively). Univariate analysis revealed that DFI <1 year was an unfavorable prognostic factor for OS (p = 0.005); N2 pathological status and presence of adenocarcinoma components were unfavorable prognostic factors for DFS (p = 0.038 and p = 0.036, respectively). CONCLUSION PPC patients with an adenocarcinoma component and N2 pathological status may have an earlier relapse and poorer prognosis than their counterparts. Further assessment of cases may help clarify the predictors of PPC.
Collapse
Affiliation(s)
- Yoshihito Iijima
- Division of Thoracic Surgery, Saitama Cancer Center, Ina, Saitama, Japan
| | - Yuki Nakajima
- Division of Thoracic Surgery, Saitama Cancer Center, Ina, Saitama, Japan
| | - Hiroyasu Kinoshita
- Division of Thoracic Surgery, Saitama Cancer Center, Ina, Saitama, Japan
| | - Yu Nishimura
- Division of Pathology, Saitama Cancer Center, Ina, Saitama, Japan
| | - Toshihiko Iizuka
- Division of Pathology, Saitama Cancer Center, Ina, Saitama, Japan
| | - Hirohiko Akiyama
- Division of Thoracic Surgery, Saitama Cancer Center, Ina, Saitama, Japan
| | - Tomomi Hirata
- Division of Thoracic Surgery, Saitama Cancer Center, Ina, Saitama, Japan
| |
Collapse
|
7
|
Iijima Y, Nakajima Y, Kinoshita H, Kurihara Y, Nishimura Y, Iizuka T, Akiyama H, Hirata T. A case of resected primary pulmonary pleomorphic carcinoma with long-term survival after multidisciplinary treatment. Surg Case Rep 2020; 6:28. [PMID: 31993853 PMCID: PMC6987290 DOI: 10.1186/s40792-020-0794-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 01/14/2020] [Indexed: 12/31/2022] Open
Abstract
Background Generally, primary pulmonary pleomorphic carcinoma is resistant to treatment and has a poor prognosis. We report a case of resected primary pulmonary pleomorphic carcinoma with long-term survival after multidisciplinary treatment. Case presentation A 74-year-old man with a history of emphysema, pneumoconiosis, and chronic bronchitis presented with left lung nodule and left adrenal tumor based on computed tomography. We suspected clinical T1bN0M1b, stage IVB lung cancer. Adrenalectomy of the left adrenal tumor yielded a definitive diagnosis of pleomorphic carcinoma. Chemotherapy was performed despite the spontaneous regression of lung lesions. Since lung lesions re-enlarged 11 months after adrenalectomy, the left lower lobe was partially resected followed by chemotherapy. The lung lesion was the primary lesion of the adrenal tumor. There was no recurrence 100 months after the lung resection. Conclusions The patient experienced long-term survival after multidisciplinary treatment. Both multidisciplinary treatment and immunological mechanisms caused spontaneous regression of the primary lesion.
Collapse
Affiliation(s)
- Yoshihito Iijima
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan.
| | - Yuki Nakajima
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan
| | - Hiroyasu Kinoshita
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan
| | - Yasuyuki Kurihara
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan
| | - Yu Nishimura
- Division of Pathology, Saitama Cancer Center, Saitama, Japan
| | | | - Hirohiko Akiyama
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan
| | - Tomomi Hirata
- Division of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita adachi-gun, Saitama, 362-0806, Japan
| |
Collapse
|
8
|
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. Target Oncol 2019; 13:631-639. [PMID: 30218431 DOI: 10.1007/s11523-018-0592-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Oncogenic fusion genes consisting of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) can be detected in 5-7% of lung adenocarcinoma cases. The prevalence of ALK rearrangement in non-adenocarcinoma, non-small cell lung cancers (NA-NSCLC) is currently unknown. In addition, the efficacy of crizotinib in these patients has not been well established. OBJECTIVES The aim of this study was to investigate the prevalence of ALK rearrangement in NA-NSCLC patients and the therapeutic efficacy of crizotinib in these patients. METHODS We included NA-NSCLC patients who were tested for the presence of ALK rearrangement in our institution from January 2013 to May 2018. The effectiveness of crizotinib in ALK-positive patients was retrospectively analyzed. A literature review was performed and eligible previously published cases were analyzed in combination with our data. RESULTS A total of 4662 patients were screened and 1696 NA-NSCLC patients were tested for the presence of ALK rearrangement during the study period. Thirty-two positive patients were identified (1.9%, 95% CI, 1.2-2.5%). A statistically higher percentage of younger (58.0 vs. 63.0, p = 0.01), female patients (53.1% vs. 10.8%, p < 0.01) who were non-smokers (71.9% vs. 40.6%, p < 0.01) and whose tumors contained adenocarcinoma components (34.4% vs. 6.1%, p < 0.01) were observed in the ALK-positive group. Eighteen patients were excluded from the study and 14 eligible patients were included for survival analysis. The median duration of crizotinib treatment (MDT) as a proxy for progression-free survival of the 14 eligible patients in our institution was 6.0 months (95% CI, 1.2-10.8 months). We combined our data with sporadic cases from 16 previous publications (total n = 37) and found that the MDT was 7.0 months (95% CI, 6.0-8.0 months). CONCLUSIONS Our study suggests the opportunity to test ALK rearrangement in NA-NSCLC patients, especially in younger, female, non-smoking patients containing adenocarcinoma components. Crizotinib provides an option for the treatment of NA-NSCLC patients who have an ALK rearrangement.
Collapse
|
9
|
Yang Y, Mei J, Lin F. Pleomorphic carcinoma of the lung: from thin-walled cavity to solid tumor. ANNALS OF TRANSLATIONAL MEDICINE 2019; 7:273. [PMID: 31355240 DOI: 10.21037/atm.2019.05.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Pulmonary pleomorphic carcinoma accounts for less than 1% of all lung malignancies. It is more aggressive than other forms of non-small cell lung cancer, and usually presented as a solid mass on computed tomography scan. However, a thin-walled lung cavity is more suggestive of a benign lesion in generally. Here we encountered a 39-year-old woman, who had been found a thin-walled cavity in her lung occasionally, whose chest computed tomography initially presented as a thin-walled lung cavity which was considered to be a benign lung cyst, became a solid tumor after 3 years. Then she underwent video-assisted thoracoscopic left lower lobectomy and lymphadenectomy, postoperative pathological examination demonstrated the diagnosis of pleomorphic carcinoma.
Collapse
Affiliation(s)
- Yanbo Yang
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Jiandong Mei
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Feng Lin
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|